Compare GOOS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | IVA |
|---|---|---|
| Founded | 1957 | 2011 |
| Country | Canada | France |
| Employees | 4289 | 77 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 1.1B |
| IPO Year | 2016 | N/A |
| Metric | GOOS | IVA |
|---|---|---|
| Price | $10.01 | $4.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $12.60 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 638.6K | 225.6K |
| Earning Date | 05-20-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $5.16 | $751.20 |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $2.94 |
| 52 Week High | $15.43 | $7.98 |
| Indicator | GOOS | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 37.62 |
| Support Level | $9.30 | $4.45 |
| Resistance Level | $14.45 | $6.24 |
| Average True Range (ATR) | 0.46 | 0.25 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 31.36 | 11.02 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale; Direct to Consumer (DTC), and Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia-Pacific, and Europe, the Middle East, and Africa.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.